Last reviewed · How we verify
Lundbeck LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
3 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sabril® | Sabril® | marketed | GABA transaminase inhibitor | GABA transaminase (ABAT) | Neurology | |
| Clobazam Medium Dose | Clobazam Medium Dose | phase 3 | Benzodiazepine | GABA-A receptor | Neurology | |
| Clobazam High Dose | Clobazam High Dose | phase 3 | Benzodiazepine | GABA-A receptor | Neurology | |
| Clobazam Low Dose | Clobazam Low Dose | phase 3 | Benzodiazepine anticonvulsant | GABA-A receptor | Neurology |
Therapeutic area mix
- Neurology · 4
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ajenat Pharms · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bausch Health · 1 shared drug class
- Centro Medico Nacional La Raza, IMSS · 1 shared drug class
- Chang Gung Memorial Hospital · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Lundbeck LLC:
- Lundbeck LLC pipeline updates — RSS
- Lundbeck LLC pipeline updates — Atom
- Lundbeck LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Lundbeck LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lundbeck-llc. Accessed 2026-05-14.